Ebola Vaccines

Viral vector vaccines

This page catalogs 2 Ebola vaccine products. The development of Ebola vaccines accelerated dramatically during the 2014–2016 West Africa epidemic, leading to the first FDA-approved Ebola vaccine (ERVEBO) in 2019. Both products use viral vector technology.

Last updated: April 2026.

Ebola Vaccine Catalog

Trade Name Generic Designation Manufacturer Vaccine Type Regulatory Status & Year Key Notes
ERVEBO Ebola Zaire vaccine, live (rVSV-ZEBOV) Merck Live recombinant viral vector FDA Licensed, 2019 First FDA-approved Ebola vaccine
Zabdeno + Mvabea Ad26.ZEBOV + MVA-BN-Filo (2-dose regimen) Janssen/Bavarian Nordic Adenovirus vector + MVA EMA Authorized, 2020 Heterologous 2-dose Ebola regimen

Sources

Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026) and EMA Medicines database. Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.

Related Pages on VaccinationFacts.com

Vaccine Catalog

Browse all vaccine categories

Vaccine History Timeline

Milestones in vaccine development